Companies › Aimei Vacin BioPharm (Zhejiang)
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 23-valent pneumococcal polysaccharide vaccine Polysaccharide antigen vaccine against 23 pneumococcal serotypes | – | Phase 3 | Pneumococcal Disease | Jul 2029 |
| Tetanus Vaccine, Adsorbed (manufactured by AIM Persistence Biopharmaceutical Co. Tetanus toxoid vaccine | – | Phase 1 | Tetanus | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07598890 | Tetanus Vaccine, Adsorbed (manufactured by AIM Persistence Biopharmaceutical Co. | Phase 1 | Tetanus | Infectious disease | Dec 2026 |
| NCT06044077 | 23-valent pneumococcal polysaccharide vaccine | Phase 3 | Pneumococcal Disease | Infectious disease | Jul 2029 |
No annotated target.
–
InventVacc Biologicals MAXVAX Biotechnology Limited Liability Company Anhui Zhifei Longcom Biologic Pharmacy Biothervax Shenzhen Shenxin Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.